enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication therapy optimization (MTO), to deliver personalized, data-driven medication guidance for clients and members worldwide.
The collaboration combines DecisionRX’s advanced pharmacogenomics platform and analytics with Benecard PBF’s outcome-based, transparent benefit model, aiming to improve health outcomes, minimize medication failures, and generate cost savings for health plans and employers.
A New Standard in Pharmacy Benefit Management
As part of the partnership, both organizations will share equal responsibility and commitment. DecisionRX brings its MTO solution to the table leveraging clinical pharmacists, prescription intelligence, and genomic data to assess the effectiveness, safety, and personalization of treatments. Meanwhile, Benecard PBF continues to elevate its pharmacy benefits offering through its member-first approach and auditable, transparent pricing model.
Together, they will offer value-based, risk-sharing options for plan sponsors, aligning financial incentives with measurable health improvements and cost efficiencies.
One of the key benefits of the partnership is the ability to reduce trial-and-error prescribing. Patients and providers will receive medication guidance based on genomic and claims data, helping to enhance therapeutic precision and reduce unnecessary healthcare spending.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
DecisionRX’s MTO platform has shown potential to reduce the annual cost of care by $1,200 for individuals under 65 and by $3,600 per Medicare patient, according to internal estimates.
Leadership Perspectives
Jeff Shea, President of Benecard PBF, emphasized the transformative nature of the alliance:
“At Benecard PBF, we’ve always believed in the power of pharmacogenomics. This partnership is more than just innovation it’s about turning insights into real-time, evidence-based care. Our role goes beyond managing benefits we’re here to facilitate better health outcomes.”
Travis Morgan, Co-founder and President of DecisionRX, expressed optimism about the collaboration:
“We’re thrilled to work with Benecard PBF to bring our MTO platform to a broader population. Benecard truly understands that medication therapy optimization is not just about cutting costs it’s about maximizing impact on patient lives.”
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More
The Direct-To-Consumer Genetic Testing Market is witnessing a global transformation, driven by the growing consumer demand for personalized healthcare insights.… Read More